Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled multiple ascending-dose study of inhaled SV001 in idiopathic pulmonary fibrosis
CTR20252760Phase 2Active
- Sponsor
- Xunyao Biotech
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SV001 in idiopathic pulmonary fibrosis (IPF), sponsored by Xunyao Biotech. Started Nov 2025; status: active.
02
Drugs
SV001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20252760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252760.